Insider Buying: PROCEPT BioRobotics (NASDAQ:PRCT) Director Acquires 98,699 Shares of Stock

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Director Antal Rohit Desai acquired 98,699 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was purchased at an average price of $24.55 per share, with a total value of $2,423,060.45. Following the acquisition, the director owned 426,262 shares of the company’s stock, valued at $10,464,732.10. This represents a 30.13% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Antal Rohit Desai also recently made the following trade(s):

• On Friday, March 6th, Antal Rohit Desai purchased 160,317 shares of PROCEPT BioRobotics stock. The shares were acquired at an average cost of $23.59 per share, with a total value of $3,781,878.03.
• On Thursday, March 5th, Antal Rohit Desai acquired 167,246 shares of PROCEPT BioRobotics stock. The shares were acquired at an average cost of $25.58 per share, for a total transaction of $4,278,152.68.

PROCEPT BioRobotics Stock Up 4.3%

PRCT traded up $1.04 during midday trading on Monday, reaching $25.26. The company’s stock had a trading volume of 2,163,428 shares, compared to its average volume of 1,640,943. PROCEPT BioRobotics Corporation has a 1 year low of $19.35 and a 1 year high of $66.85. The stock’s 50-day moving average is $29.11 and its 200-day moving average is $32.83. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -14.77 and a beta of 1.03. The company has a current ratio of 6.85, a quick ratio of 5.77 and a debt-to-equity ratio of 0.14.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). The company had revenue of $76.38 million during the quarter, compared to the consensus estimate of $93.70 million. PROCEPT BioRobotics had a negative return on equity of 25.13% and a negative net margin of 31.02%.The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.35) earnings per share. As a group, research analysts expect that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current year.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Director Antal Rohit Desai completed a series of large open‑market purchases March 5–9, increasing his stake to 426,262 shares; the three Form 4 filings show roughly $10.5M of insider buying over those days — a strong bullish signal that executives view the stock as undervalued. Insider Purchase Filings
• Positive Sentiment: Research coverage was initiated at Robert W. Baird, which can increase visibility and trading interest (Baird’s note content/rating not included in the filing). Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Two senior executives (EVPs Kevin Waters and Alaleh Nouri) sold small stakes (6,721 and 6,892 shares respectively on March 6) for a combined ~13.6k shares (~$322k), likely personal liquidity rather than a company signal given the scale relative to the director’s purchases. Kevin Waters Sale Filing Alaleh Nouri Sale Filing
• Negative Sentiment: Two law firms (Levi & Korsinsky and Schall) announced securities‑fraud investigations related to PROCEPT’s prior guidance and statements (citing prior revenue targets and handpiece pricing comments). Such investigations raise the risk of litigation, distraction and potential disclosures or restatements — a clear negative catalyst for sentiment. Levi & Korsinsky Investigation Notice Schall Law Firm Investigation Notice

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PRCT. UBS Group initiated coverage on shares of PROCEPT BioRobotics in a research note on Friday, December 12th. They issued a “buy” rating and a $62.00 price target on the stock. Jefferies Financial Group downgraded shares of PROCEPT BioRobotics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 26th. Morgan Stanley reduced their price target on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating for the company in a research report on Tuesday, December 2nd. Robert W. Baird assumed coverage on PROCEPT BioRobotics in a research report on Friday. They issued a “neutral” rating and a $30.00 price objective on the stock. Finally, Leerink Partners reduced their target price on PROCEPT BioRobotics from $55.00 to $30.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $40.82.

Hedge Funds Weigh In On PROCEPT BioRobotics

A number of institutional investors and hedge funds have recently modified their holdings of PRCT. Prosight Management LP grew its holdings in shares of PROCEPT BioRobotics by 1,692.4% in the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock worth $43,415,000 after acquiring an additional 1,303,009 shares during the period. Alliancebernstein L.P. grew its stake in shares of PROCEPT BioRobotics by 58.6% during the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after purchasing an additional 1,262,928 shares during the period. T. Rowe Price Investment Management Inc. increased its position in shares of PROCEPT BioRobotics by 59.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock valued at $102,919,000 after purchasing an additional 1,218,815 shares during the last quarter. Chicago Capital LLC lifted its stake in shares of PROCEPT BioRobotics by 175.7% in the 3rd quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock worth $55,992,000 after purchasing an additional 999,873 shares during the period. Finally, Westfield Capital Management Co. LP boosted its holdings in shares of PROCEPT BioRobotics by 113.5% in the second quarter. Westfield Capital Management Co. LP now owns 1,598,349 shares of the company’s stock worth $92,065,000 after buying an additional 849,792 shares during the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.